We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Category:Active Pharmaceutical Ingredients > Other Active Pharmaceutical Ingredients Product Name:EPIAO CAS No.:- Standard:In-house Standards Price(USD):0.00 Company:3SBIO INC.
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Erythropoietin is a glycoprotein that excreted in the kidney and stimulates the proliferation and differentiation of committed erythroid progenitors in the bone marrow. It can increase the production of Red Blood Cells.
Indications: Anemia associated with renal failure: including patients on hemodialysis (HD) and non-dialysis (ND), peri-operative red blood cell mobilization, and anemia associated with chemotherapy in cancer patients with non-myeloid malignancies. EPIAO is firstly approved for the treatment of peri-operative red blood cell mobilization and anemia associated with chemotherapy in cancer patients in China.
10,000IU/vial is the unique specification developed by 3SBio, which could be used conveniently in all above-mentioned indications. In 2011, the SFDA approved a 36,000 IU formulation for chemotherapy indications
Seven years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
